Tag:

NeuroScience Pharmaceuticals

Latest Headlines

Start-up licenses mid-stage schizophrenia drug

April 21, 2009

Veteran biotech executive Gabriel Cipau has launched a new developer in Research Triangle Park. NeuroScience Pharmaceuticals has licensed a program from Duke University and the Durham Veterans

THE LIBRARY: WEBINAR

Getting the most PoC data in Phase I cancer studies

| June 12, 11am ET/ 8am PT

The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!

MORE ITEMS

EVENTS

MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
What's your BIO?June 18-21, 2012 — Boston, MA

MORE EVENTS

Press Releases

Featured Jobs

Supervisor, QC Chemistry - 3rd Shift Job
Celgene Corporation - Phoenix, AZ, US
Process Development Scientist - Downstream Job
Yoh - Durham, NC, USA
Senior Manager, API Development
TESARO - Waltham, MA
Senior Scientist - Permanent Job
Yoh - Doylestown, PA, USA
Regulatory Scientist Assistant III (Senior) Job
Yoh - Kenilworth, NJ, USA

NeuroScience Pharmaceuticals

Latest Headlines

Latest Headlines

Start-up licenses mid-stage schizophrenia drug

THE LIBRARY: WEBINAR

EVENTS

Press Releases

Featured Jobs

A publication of FierceMarkets

The FierceMarkets Network:

Telecom

Healthcare

Government

Energy

Life Sciences

Enterprise IT

Finance

NeuroScience Pharmaceuticals

Latest Headlines

Latest Headlines

Start-up licenses mid-stage schizophrenia drug

Related Tags